IQVIA Holdings (I1QV34) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of IQVIA Holdings BRL 31.58, price BRL 84.40, upside -62.6%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range R$49.30 – R$99.74 · fair‑value band R$16.70 – R$51.48 · the R$84.40 price screens above the R$31.58 fair value. Dashed = 300-day average. As of Oct 3, 2026.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Show more
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Stock analysis
IQVIA Holdings (I1QV34) currently trades at R$84.40, while our model-based Fair Value estimate is R$31.58, 62.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of R$47.99 per share, and 0 of the 23 models we run sit above the R$84.40 price.
Bear case: the Asset-Based group reads lowest at R$8.52, and 23 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: R$16.70 (bear) to R$51.48 (bull), the price of R$84.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
IQVIA Holdings reported revenue of $16.3B in FY2025 versus $14.4B in FY2022, a compound +4.2%/yr. Reported net income was $1.4B in FY2025, compounding +7.6%/yr from FY2022.
Key figures
Market cap R$175B (≈ $33.6B) · P/E ratio 25.2 · P/S ratio 2.10 · EPS (TTM) R$10.43 · Net margin 8.3% · Return on equity 22.5% · Return on assets (EBIT) 7.5% · Operating margin 13.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −63%, I1QV34 screens richer than that median.
Fair Value models
Bear R$16.70Fair Value R$31.58Bull R$51.48
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$7.89 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.3%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 13%
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "IQVIA Holdings Fair Value". https://www.fairvalue-calculator.com/stock/I1QV34
Frequently asked questions
Is IQVIA Holdings (I1QV34) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of R$31.58 versus a price of R$84.40, about −63% upside (overvalued).
What is the fair value of I1QV34?
Our model-based fair value for IQVIA Holdings is R$31.58 (as of Oct 3, 2026), built from audited fundamentals. The current price: R$84.40.
What is the quality score of I1QV34?
IQVIA Holdings has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IQVIA Holdings (I1QV34)?
Our model-based price target is the fair value of R$31.58 (as of Oct 3, 2026) from 23 valuation models. Cautious scenario R$16.70, optimistic scenario R$51.48. It is a calculation from audited fundamentals, not an analyst target.
What is the IQVIA Holdings stock forecast for 2026?
Our models put fair value at R$31.58, about −63% upside versus a price of R$84.40 (overvalued). Cautious scenario R$16.70, optimistic scenario R$51.48. The calculation is refreshed regularly with new filings.
What is the revenue of IQVIA Holdings (I1QV34)?
IQVIA Holdings reported trailing-twelve-month revenue of about $16.6B (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of IQVIA Holdings (I1QV34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IQVIA Holdings it is R$31.58 per share (as of Oct 3, 2026), against a price of R$84.40. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is IQVIA Holdings stock overvalued or undervalued in 2026?
As of Oct 3, 2026, I1QV34 trades above its calculated fair value: price R$84.40, fair value R$31.58, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of I1QV34?
No. The price is what the market pays today (R$84.40); the fair value is what the company's own numbers justify (R$31.58). For IQVIA Holdings the two are R$52.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is IQVIA Holdings worth?
The market values IQVIA Holdings at about R$175B (market capitalisation, as of Oct 3, 2026). Per share that is R$84.40; our models calculate a fair value of R$31.58 per share.
What do the bullish and bearish scenarios say about I1QV34?
Our models span a range for IQVIA Holdings: cautious scenario R$16.70, base R$31.58, optimistic R$51.48 per share (as of Oct 3, 2026, price R$84.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is I1QV34 from its 52-week high?
IQVIA Holdings trades at R$84.40, about 2% below its 52-week high of R$86.31 and 71% above the low of R$49.30 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of R$31.58 is for.
Which stocks are comparable to IQVIA Holdings?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IQVIA Holdings stock attractive at the current price?
The data as of Oct 3, 2026: price R$84.40, calculated fair value R$31.58 (−63%), Quality Score 62/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of I1QV34 calculated?
We run IQVIA Holdings through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$31.58, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. IQVIA Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IQVIA Holdings (I1QV34)?
The closing price on Oct 1, 2026 was R$84.40. Our model-based fair value is R$31.58, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IQVIA Holdings right now?
The price sits above even our optimistic bull case (R$51.48). The favourable scenario is already priced in. The model range is unusually wide (R$16.70 to R$51.48). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of IQVIA Holdings
How large is the market capitalisation of IQVIA Holdings (I1QV34)?
The market capitalisation of IQVIA Holdings is R$175B (≈ $33.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of IQVIA Holdings (I1QV34)?
The price-to-earnings ratio of IQVIA Holdings is 25.2 (as of Jul 18, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of IQVIA Holdings (I1QV34)?
The price-to-sales ratio of IQVIA Holdings is 2.10 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IQVIA Holdings (I1QV34)?
Earnings per share at IQVIA Holdings are R$10.43 (price ÷ EPS = P/E 25.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of IQVIA Holdings (I1QV34)?
The net margin of IQVIA Holdings is 8.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IQVIA Holdings (I1QV34)?
The return on equity (ROE) of IQVIA Holdings is 22.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IQVIA Holdings (I1QV34)?
On an EBIT basis the return on assets of IQVIA Holdings is 7.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IQVIA Holdings (I1QV34)?
The operating margin of IQVIA Holdings is 13.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IQVIA Holdings (I1QV34)?
Revenue at IQVIA Holdings is growing +8.4% versus a year earlier (3y avg +4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at IQVIA Holdings (I1QV34)?
Earnings per share at IQVIA Holdings are growing +15.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does IQVIA Holdings (I1QV34) generate?
The free cash flow of IQVIA Holdings is $2.1B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does IQVIA Holdings (I1QV34) carry?
The net debt of IQVIA Holdings is $13.7B (fiscal year 2025, ≈ 6.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
